Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Raw Materials (2016 - 2025)

Sonoma Pharmaceuticals has reported Raw Materials over the past 13 years, most recently at $2.1 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 50.29% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 50.29%, while the annual FY2025 figure was $1.4 million, 22.59% down from the prior year.
  • Raw Materials for Q4 2025 was $2.1 million at Sonoma Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Over five years, Raw Materials peaked at $2.1 million in Q4 2025 and troughed at $1.4 million in Q4 2024.
  • A 5-year average of $1.7 million and a median of $1.6 million in 2021 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: tumbled 40.81% in 2021 and later skyrocketed 50.29% in 2025.
  • Year by year, Raw Materials stood at $1.6 million in 2021, then fell by 0.98% to $1.6 million in 2022, then decreased by 6.46% to $1.5 million in 2023, then dropped by 8.69% to $1.4 million in 2024, then skyrocketed by 50.29% to $2.1 million in 2025.
  • Business Quant data shows Raw Materials for SNOA at $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $1.8 million in Q2 2025.